Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2019 / Article

Erratum | Open Access

Volume 2019 |Article ID 5741476 | 2 pages | https://doi.org/10.1155/2019/5741476

Erratum to “Melatonin Suppresses the Expression of 45S Preribosomal RNA and Upstream Binding Factor and Enhances the Antitumor Activity of Puromycin in MDA-MB-231 Breast Cancer Cells”

Received02 Jul 2019
Accepted04 Jul 2019
Published21 Jul 2019

In the article titled “Melatonin Suppresses the Expression of 45S Preribosomal RNA and Upstream Binding Factor and Enhances the Antitumor Activity of Puromycin in MDA-MB-231 Breast Cancer Cells” [1], there was an error in Figure 3(a), where the fifth lane (Mcl-1) was mistakenly duplicated with the sixth lane (Cyclin D1), due to a production error. The correct figure is shown below.

References

  1. J. H. Jung, E. J. Sohn, E. A. Shin et al., “Melatonin suppresses the expression of 45S preribosomal RNA and upstream binding factor and enhances the antitumor activity of puromycin in MDA-MB-231 breast cancer cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 879746, 8 pages, 2013. View at: Publisher Site | Google Scholar

Copyright © 2019 Ji Hoon Jung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

382 Views | 185 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.